Thursday 16 October, 2025
Objectives: Bispecific monoclonal antibodies (BsMAb) are created from two different MAbs that bind simultaneously to two different types of targets….
Read morePoster: Methodology - New Modelling Approaches
Characterization of bispecific antibodies and the ternary complex including an optimal dosing strategy
Thursday 16 October, 2025
Objectives: Bispecific monoclonal antibodies (BsMabs) are promising candidates in cancer immunotherapy. For example, BsMabs may simultaneously bind a T cell…
Read moreNovel integrated population PD modeling framework to inform decision making during Oncology phase I dose-escalation
Thursday 16 October, 2025
Introduction: Oncology phase I dose escalation (DE) trials enroll cohorts of 3-6 patients to increasing doses of an experimental drug. As…
Read moreQualifying drug dosing regimens in pediatrics using Gaussian Processes
Thursday 16 October, 2025
Objectives Pediatric drug development is lagged w.r.t. to the respective adult program. Knowledge about a safe and efficacious regimen is…
Read moreThe minimal continuous-time Markov pharmacometric model
Thursday 16 October, 2025
Objectives: To present the minimal continuous-time Markov model (mCTMM) as an alternative to discrete-time Markov model (DTMM) or standard CTMM…
Read moreDetermination of Appropriate Settings in the Assessment of Parameter Uncertainty Distributions using Sampling Importance Resampling (SIR)
Thursday 16 October, 2025
Objectives: Sampling Importance Resampling (SIR) [1] has been proposed as a method for assessment of parameter uncertainty without the need for…
Read moreCan mAb dose selection in IBD be supported by public domain data from other immune-mediated inflammatory diseases?
Thursday 16 October, 2025
Objectives: Biologics and small-molecule drugs have proven efficacy across many disease states and have revolutionized the treatment of immune-mediated inflammatory…
Read moreAn In Vitro – In Vivo Simulation Methodology for Predicting the Outcome of Bioequivalence Studies
Thursday 16 October, 2025
Introduction: The role of modeling and simulation methodologies in drug development is emerging. Objectives: To develop an in vitro –…
Read moreArtificial intelligence and machine learning: just a hype or a new opportunity for pharmacometrics?
Thursday 16 October, 2025
Objectives:Artificial Intelligence (AI) in drug development has attracted a growing interest [1]. AI deals with computer systems able to perform…
Read moreCombining Reinforcement Learning and PK-PD models to personalize multiple drug administration: an application to Axitinib-Anti-Hypertensive treatment in metastatic renal cancer patients
Thursday 16 October, 2025
Objectives: Reinforcement Learning (RL) is a class of Machine Learning algorithms designed to solve sequential decision-making problems [1]. Recently, the…
Read more